Dataset Information


Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

ABSTRACT: Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripheral blood and lymphoid organs. CDX-301 has an identical amino-acid sequence and comparable biological activity to the previously tested rhuFlt3L, which ceased clinical development over a decade ago. This Phase 1 trial assessed the safety, pharmacokinetic, pharmacodynamic and immunologic profile of CDX-301, explored alternate dosing regimens and examined the impact of rhuFlt3L on key immune cell subsets. Thirty healthy volunteers received CDX-301 (1-75 ?g/kg/day) over 5-10 days. One event of Grade 3 community-acquired pneumonia occurred. There were no other infections, dose-limiting toxicities or serious adverse events. CDX-301 resulted in effective peripheral expansion of monocytes, hematopoietic stem and progenitor cells and key subsets of myeloid DCs and plasmacytoid DCs, with no clear effect on regulatory T cells. These data from healthy volunteers support the potential for CDX-301, as monotherapy or in combination with other agents, in various indications including allogeneic HSC transplantation and immunotherapy, but the effects of CDX-301 will need to be investigated in each of these patient populations.

SUBMITTER: Anandasabapathy N 

PROVIDER: S-EPMC4532305 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3978611 | BioStudies
2008-01-01 | S-EPMC2409377 | BioStudies
2008-01-01 | S-EPMC2384126 | BioStudies
2016-01-01 | S-EPMC5160023 | BioStudies
2018-01-01 | S-EPMC6272106 | BioStudies
2011-01-01 | S-EPMC3116010 | BioStudies
2011-01-01 | S-EPMC4291128 | BioStudies
2020-01-01 | S-EPMC7378358 | BioStudies
2011-01-01 | S-EPMC3502019 | BioStudies
2014-01-01 | S-EPMC3994898 | BioStudies